ARTICLE
20 September 2022

BIS Proposes Automated Peptide Synthesizers For Section 1758 Critical Technology Controls

WT
Winston Taylor

Contributor

Whether you're leading the way, disrupting an industry, entering a new phase of growth, or launching a defining product—we're in the room with you. In the action. Sleeves rolled up.

With a rich history spanning both sides of the Atlantic, we are present in the major commercial centers that matter to our clients: the U.S., the U.K., Europe, Latin America, and the Middle East. Combining scale with the speed clients demand, our defining capabilities include major litigation, critical transactions, strategic IP, and private wealth.

Our team of over 1,400 lawyers works hand-in-hand across markets, sectors, practice areas, and client teams. All-in problem solvers, we bring the creativity to think differently, and the pragmatism to get things done when it counts the most.

Embedded in your business and sharing your ambition, we take the work personally. Shaping what we do and how we do it around your goals and needs, always one step ahead of the moment.

On September 13, 2022, the U.S. Department of Commerce's Bureau of Industry and Security ("BIS") published an advance notice of proposed rulemaking ("ANPRM") to...
United States International Law

On September 13, 2022, the U.S. Department of Commerce's Bureau of Industry and Security ("BIS") published an advance notice of proposed rulemaking ("ANPRM") to impose export controls on automated peptide synthesizers and associated software and technology under Section 1758 of the Export Control Reform Act. BIS noted in the ANPRM that Export Control Classification Number ("ECCN") 1C351 currently contains mostly advanced peptides and proteins that could be used as toxins for biological weapons purposes, but there is no appropriate control on the automated synthesizers or associated software and technology capable of producing those toxins.

If implemented, companies producing such hardware, software, or technology in the U.S. or outside the U.S. under more limited circumstances would need to comply with the Export Administration Regulations ("EAR") with respect to the automated peptide synthesizers. At a minimum, the export controls imposed under Section 1758 would require a license for export, reexport, or transfer to or within countries subject to a comprehensive U.S. embargo, including the wider group of countries subject to the U.S. arms embargoes. Additionally, designation of the automated peptide synthesizers and related software and technology under Section 1758 will result in any U.S. company that produces, designs, tests, manufactures, fabricates, or develops these items or associated software or technology fitting the definition of a "TID U.S. business" for Committee on Foreign Investment in the United States ("CFIUS") purposes.

The ANPRM requests comments on eight (8) subjects by October 28, 2022. Please contact the authors or your Winston relationship partner if you have questions, would like assistance submitting a comment, or wish to be added to our mailing list. Winston's international trade lawyers located in offices around the world have expertise in export controls, sanctions, import requirements, anti-corruption and anti-bribery laws, anti-money laundering laws, and Committee on Foreign Investment in the United States national security reviews.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More